---
title: Antiparasitic Drugs
type: content
phase: 1
status: complete
priority: high
tags: [antiparasitics, antimalarials, antihelminthics, chloroquine, artemisinin, mebendazole, ivermectin, metronidazole, parasites]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antiparasitic Drugs

## Introduction

Parasitic infections affect billions worldwide, causing significant morbidity and mortality, particularly in resource-limited settings. Antiparasitic drugs target protozoa, helminths (worms), and ectoparasites. Understanding parasite biology and drug mechanisms is essential for effective treatment and prophylaxis.

## Classification

**Protozoal infections**: Malaria, amebiasis, giardiasis, toxoplasmosis, leishmaniasis, trypanosomiasis
**Helminth infections**: Nematodes (roundworms), trematodes (flukes), cestodes (tapeworms)
**Ectoparasites**: Scabies, lice

---

## Antimalarial Drugs

### Overview of Malaria

**Plasmodium species**: P. falciparum (most deadly), P. vivax, P. ovale, P. malariae, P. knowlesi

**Life Cycle**:
- **Liver stage** (hypnozoites in P. vivax, P. ovale)
- **Blood stage** (erythrocytic)
- **Gametocytes** (transmission to mosquitoes)

**Treatment goals**:
- Treat acute infection (blood stage)
- Prevent relapse (eradicate liver hypnozoites)
- Chemoprophylaxis

---

### Chloroquine

**Mechanism**:
- Concentrates in parasite food vacuole
- Inhibits heme polymerization
- Toxic heme accumulation → parasite death
- **Blood schizonticide** (kills erythrocytic forms)

**Spectrum**:
- **P. vivax, P. ovale, P. malariae** (chloroquine-sensitive)
- **P. falciparum**: Widespread resistance (not used in most areas)

**Pharmacokinetics**:
- Oral, excellent absorption
- Extensive tissue distribution (high Vd)
- **Long half-life** (3-5 days)
- Hepatic metabolism, renal excretion

**Clinical Uses**:
- **Chloroquine-sensitive malaria**: Treatment and prophylaxis
- **Amebiasis** (hepatic)
- **Rheumatoid arthritis, lupus** (off-label, DMARD)

**Adverse Effects**:
- **GI upset**: Nausea, vomiting, diarrhea
- **Pruritus**: Especially in dark-skinned individuals
- **Retinopathy**: Long-term use (lupus/RA)
  - Irreversible
  - Screen with ophthalmologic exams
- **Cardiotoxicity**: QT prolongation (high doses, IV)
- **Hemolysis**: In G6PD deficiency (mild)

**Resistance**:
- **Widespread in P. falciparum** (most of the world)
- Mechanism: Efflux pump mutations (pfcrt gene)

**Clinical Pearls**:
1. **Limited use** due to P. falciparum resistance
2. **Still useful** for P. vivax, P. ovale, P. malariae
3. **Ophthalmologic monitoring**: Long-term use (RA/lupus)

### Hydroxychloroquine

- Similar to chloroquine
- **Preferred for RA/lupus**: Less retinal toxicity
- Same antimalarial uses (chloroquine-sensitive areas)

### Artemisinin-Based Combination Therapies (ACTs)

**Artemisinin Derivatives**:
- Artemether, artesunate, dihydroartemisinin
- **Derived from Artemisia annua** (sweet wormwood)

**Mechanism**:
- Generates free radicals after activation by heme iron
- Damages parasite proteins and membranes
- **Rapid parasite clearance**
- Active against all stages (including gametocytes)

**ACT Regimens** (WHO-recommended):
- **Artemether-lumefantrine** (Coartem): Most widely used
- **Artesunate-amodiaquine**
- **Artesunate-mefloquine**
- **Dihydroartemisinin-piperaquine**

**Rationale for Combination**:
- Rapid kill (artemisinin)
- Long-acting partner drug (prevents recrudescence)
- Prevents resistance

**Clinical Uses**:
- **Uncomplicated P. falciparum malaria** (first-line worldwide)
- **Severe malaria**: IV artesunate (drug of choice)

**Artemether-Lumefantrine (Coartem)**:
- Oral, 3-day course
- Take with fatty food (↑lumefantrine absorption)
- Well-tolerated
- **Adverse effects**: Headache, dizziness, GI upset

**IV Artesunate**:
- **Severe malaria** (drug of choice, replaced quinine)
- Rapid parasite clearance
- ↓Mortality vs. quinine
- **Adverse effect**: Delayed hemolysis (10-14 days post-treatment)

**Resistance**:
- Emerging in Southeast Asia (artemisinin resistance)
- Delayed parasite clearance
- ACTs still effective (partner drug)

### Atovaquone-Proguanil (Malarone)

**Mechanism**:
- **Atovaquone**: Inhibits mitochondrial electron transport
- **Proguanil**: Inhibits dihydrofolate reductase, enhances atovaquone
- Synergistic combination

**Clinical Uses**:
- **Malaria prophylaxis** (travelers)
- **Treatment**: Uncomplicated P. falciparum (alternative to ACT)

**Advantages**:
- Well-tolerated
- Short course prophylaxis (start 1-2 days before travel, continue 7 days after)
- No loading dose

**Adverse Effects**:
- GI upset (mild)
- Headache
- Rash

**Limitations**:
- Expensive
- Not for severe malaria

### Mefloquine (Lariam)

**Mechanism**:
- Similar to chloroquine (inhibits heme polymerization)
- Blood schizonticide

**Clinical Uses**:
- **Malaria prophylaxis** (chloroquine-resistant areas)
- **Treatment** (in ACT combinations)

**Adverse Effects**:
- **Neuropsychiatric** (black box warning):
  - Anxiety, depression, psychosis
  - Nightmares, insomnia
  - Seizures
  - Can persist after discontinuation
- **GI upset**
- **Cardiotoxicity**: QT prolongation

**Contraindications**:
- Psychiatric disorders
- Seizure disorders
- Cardiac conduction abnormalities

**Clinical Pearl**: **Neuropsychiatric effects** limit use; alternatives preferred

### Primaquine

**Unique Property**:
- **Only drug** that eradicates **liver hypnozoites** (P. vivax, P. ovale)
- Prevents relapse (radical cure)
- Also kills gametocytes (prevents transmission)

**Mechanism**:
- Generates oxidative stress
- Exact mechanism unclear

**Clinical Uses**:
- **P. vivax/P. ovale**: Eradicate liver stage (after chloroquine/ACT for blood stage)
- **P. falciparum**: Terminal prophylaxis (after leaving endemic area)

**Adverse Effects**:
- **Hemolytic anemia in G6PD deficiency**:
  - **Screen for G6PD** before use (mandatory)
  - Contraindicated if deficient
- **Methemoglobinemia**
- GI upset

**Dosing**:
- 14-day course (after treatment of blood stage)
- Higher doses may allow shorter courses

**Clinical Pearls**:
1. **Essential for P. vivax/ovale radical cure**
2. **G6PD testing mandatory**: Prevents severe hemolysis
3. **Pregnancy**: Contraindicated (defer until after delivery)

### Quinine/Quinidine

**Mechanism**:
- Similar to chloroquine
- Blood schizonticide

**Clinical Uses**:
- **Severe malaria**: Historical standard (replaced by artesunate)
- **Babesiosis** (with clindamycin)
- **Leg cramps** (quinine, off-label)

**Adverse Effects**:
- **Cinchonism**: Tinnitus, headache, nausea, visual disturbances
- **Hypoglycemia**: Stimulates insulin release
- **Cardiotoxicity**: QT prolongation, arrhythmias
- **Hemolysis**: Blackwater fever (severe intravascular hemolysis)

**Monitoring**:
- Blood glucose
- ECG (QT interval)

**Clinical Pearl**: **Largely replaced by artesunate** for severe malaria

---

## Antiprotozoal Drugs (Non-Malaria)

### Metronidazole (Flagyl)

**Mechanism**:
- **Prodrug**: Activated by reduction in anaerobic organisms
- Generates toxic metabolites → DNA damage
- Active against **anaerobic bacteria and protozoa**

**Spectrum**:
- **Protozoa**: Giardia, Entamoeba histolytica, Trichomonas
- **Anaerobic bacteria**: Bacteroides, Clostridium (C. diff)

**Pharmacokinetics**:
- Oral, IV
- Excellent absorption
- **Good CNS penetration**
- Hepatic metabolism

**Clinical Uses**:
- **Giardiasis** (first-line)
- **Amebiasis**: Intestinal and hepatic
- **Trichomoniasis** (vaginal, treat partners)
- **C. difficile colitis**
- **Anaerobic bacterial infections**: Intra-abdominal, pelvic, aspiration pneumonia
- **H. pylori eradication** (triple therapy)

**Dosing**:
- Varies by indication (250-750 mg TID-QID)
- Trichomoniasis: 2 g × 1 dose (or 500 mg BID × 7 days)

**Adverse Effects**:
- **Metallic taste** (common)
- **GI upset**: Nausea, anorexia
- **Disulfiram-like reaction**: With alcohol (flushing, vomiting)
  - **Avoid alcohol** during and 48 hrs after therapy
- **Peripheral neuropathy**: Prolonged use, high doses
  - Reversible if caught early
- **Seizures**: High doses
- **Dark urine**: Harmless

**Contraindications**:
- 1st trimester pregnancy (relative)
- Alcohol consumption

**Clinical Pearls**:
1. **First-line for Giardia, amebiasis, trichomoniasis**
2. **Avoid alcohol**: Disulfiram reaction
3. **Peripheral neuropathy**: Monitor in prolonged therapy

### Tinidazole

- Similar to metronidazole
- **Longer half-life**: Single-dose therapy possible
- Same indications (giardiasis, amebiasis, trichomoniasis)
- Better tolerated (less nausea)

### Nitazoxanide (Alinia)

**Spectrum**:
- **Giardia, Cryptosporidium**
- Also: C. difficile, helminths

**Clinical Uses**:
- **Giardiasis** (alternative)
- **Cryptosporidiosis** (especially in HIV/AIDS)
- **C. diff** (alternative)

**Adverse Effects**:
- Generally well-tolerated
- GI upset, headache

### Paromomycin

- Aminoglycoside antibiotic
- **Poorly absorbed** (stays in GI tract)
- **Clinical uses**:
  - **Intestinal amebiasis** (luminal agent)
  - **Cryptosporidiosis**
  - **Leishmaniasis** (parenteral form)

---

## Antihelminthic Drugs

### Benzimidazoles

**Drugs**: Mebendazole, Albendazole

**Mechanism**:
- Inhibit microtubule polymerization (bind β-tubulin)
- Impair glucose uptake
- Worm immobilization and death

**Spectrum**:
- **Broad-spectrum**:
  - **Nematodes** (roundworms): Ascaris, hookworm, Trichuris, Enterobius (pinworm)
  - **Cestodes** (tapeworms): Taenia, Echinococcus (albendazole)
  - **Trematodes** (flukes): Limited activity

#### Mebendazole (Vermox)

**Clinical Uses**:
- **Pinworm** (Enterobius vermicularis): Single dose, repeat in 2 weeks
- **Roundworm** (Ascaris lumbricoides)
- **Hookworm** (Ancylostoma, Necator)
- **Whipworm** (Trichuris trichiura)

**Dosing**:
- Pinworm: 100 mg × 1, repeat in 2 weeks
- Other: 100 mg BID × 3 days

**Adverse Effects**:
- Generally well-tolerated
- GI upset (mild)
- Abdominal pain

**Pregnancy**: Avoid (teratogenic in animals)

#### Albendazole (Albenza)

**Clinical Uses**:
- Same as mebendazole (pinworm, roundworm, hookworm, whipworm)
- **Hydatid disease** (Echinococcus): 4-6 months therapy
- **Neurocysticercosis** (Taenia solium): With corticosteroids
- **Cutaneous larva migrans**
- **Lymphatic filariasis** (with ivermectin)

**Dosing**:
- Intestinal helminths: 400 mg × 1
- Hydatid/neurocysticercosis: 400 mg BID × months

**Adverse Effects**:
- Similar to mebendazole
- **Hepatotoxicity**: Monitor LFTs (prolonged therapy)
- **Bone marrow suppression**: Monitor CBC (prolonged therapy)

**Pregnancy**: Contraindicated (1st trimester)

**Clinical Pearls**:
1. **Broad-spectrum antihelminthics**
2. **Albendazole for tissue infections**: Hydatid, neurocysticercosis
3. **Monitor LFTs, CBC**: Prolonged therapy

### Pyrantel Pamoate

**Mechanism**:
- Nicotinic agonist → depolarizing neuromuscular blockade
- Worm paralysis and expulsion

**Spectrum**:
- Pinworm (Enterobius)
- Roundworm (Ascaris)
- Hookworm

**Clinical Uses**:
- **Pinworm**: Alternative to mebendazole
- Over-the-counter availability

**Dosing**:
- 11 mg/kg × 1 (max 1 g), repeat in 2 weeks

**Adverse Effects**:
- GI upset, cramping
- Well-tolerated

**Clinical Pearl**: **OTC option** for pinworm

### Ivermectin (Stromectol)

**Mechanism**:
- Binds glutamate-gated chloride channels (invertebrates)
- Hyperpolarization → paralysis
- **Selective for parasites** (mammalian CNS protected by BBB)

**Spectrum**:
- **Nematodes**: Strongyloides, Onchocerca (river blindness), filarial worms
- **Ectoparasites**: Scabies, lice

**Clinical Uses**:
- **Strongyloidiasis**: 200 mcg/kg × 1-2 days
- **Onchocerciasis**: Annual treatment
- **Scabies**: 200 mcg/kg × 1, repeat in 1-2 weeks (especially crusted scabies)
- **Head lice**: Alternative to topical therapy
- **Cutaneous larva migrans**

**Dosing**:
- Weight-based, single dose (or 2 doses 1-2 weeks apart)

**Adverse Effects**:
- Generally well-tolerated
- **Mazzotti reaction** (onchocerciasis):
  - Pruritus, rash, lymphadenopathy
  - Due to dying microfilariae
  - Treat symptoms (antihistamines, corticosteroids)
- GI upset

**Contraindications**:
- **Loiasis** (Loa loa co-infection):
  - Risk of encephalopathy (high microfilarial load)
  - Screen before treating onchocerciasis

**Clinical Pearls**:
1. **Strongyloides**: Drug of choice (prevent hyperinfection in immunosuppressed)
2. **Scabies**: Especially crusted (Norwegian) scabies
3. **Mass drug administration**: Onchocerciasis, lymphatic filariasis (global health)

### Praziquantel (Biltricide)

**Mechanism**:
- Increases cell membrane permeability to calcium
- Worm paralysis and death
- Also triggers immune response against worm

**Spectrum**:
- **Trematodes** (flukes): Schistosoma (all species), Clonorchis, Paragonimus
- **Cestodes** (tapeworms): Taenia, Diphyllobothrium, Hymenolepis

**Clinical Uses**:
- **Schistosomiasis**: 40-60 mg/kg divided doses × 1 day
- **Intestinal tapeworms**: 5-25 mg/kg × 1
- **Neurocysticercosis**: 50 mg/kg/day ÷ TID × 10-14 days (with corticosteroids)

**Adverse Effects**:
- **GI upset**: Nausea, abdominal pain
- **CNS effects**: Dizziness, headache, drowsiness
- **Do NOT drive** on day of treatment

**Contraindications**:
- **Ocular cysticercosis**: Risk of irreversible eye damage
- **Neurocysticercosis**: Requires corticosteroids (prevent inflammation from dying cysts)

**Clinical Pearls**:
1. **Drug of choice** for schistosomiasis (all species)
2. **Single-day therapy**: Excellent for mass treatment
3. **Neurocysticercosis**: Always give with corticosteroids

### Diethylcarbamazine (DEC)

**Mechanism**:
- Unknown (alters parasite surface, enhances host immune response)

**Clinical Uses**:
- **Lymphatic filariasis** (Wuchereria bancrofti, Brugia malayi)
- **Loiasis** (Loa loa)
- **Tropical eosinophilia**

**Adverse Effects**:
- **Mazzotti-like reaction**: Dying microfilariae → fever, rash, pruritus
- GI upset

**Clinical Pearl**: **Not available in US** (WHO provides for mass drug administration)

---

## Ectoparasiticides

### Permethrin

- **Topical pyrethroid**
- **Clinical uses**:
  - **Scabies**: 5% cream, single application (repeat in 1 week)
  - **Head lice**: 1% cream rinse (Nix)
- **Mechanism**: Disrupts sodium channels → paralysis
- Very safe, first-line for scabies/lice

### Lindane

- **Organochlorine**
- **Neurotoxic**: Seizures risk
- **Second-line** (after permethrin failure)
- **Avoid**: Children, pregnancy, extensive skin disease

### Malathion

- **Organophosphate**
- **Head lice**: 0.5% lotion (Ovide)
- Apply to dry hair, leave 8-12 hours

---

## Clinical Pearls - Summary

1. **ACTs**: First-line for P. falciparum malaria
2. **Primaquine**: Only drug for P. vivax/ovale radical cure; G6PD testing mandatory
3. **Metronidazole**: Giardia, amebiasis, trichomoniasis; avoid alcohol
4. **Albendazole**: Broad-spectrum antihelminthic; tissue infections (hydatid, neurocysticercosis)
5. **Ivermectin**: Strongyloides, onchocerciasis, scabies
6. **Praziquantel**: Schistosomiasis (all species), tapeworms
7. **Permethrin**: First-line for scabies and lice
8. **G6PD screening**: Before primaquine, dapsone
9. **Mass drug administration**: Key strategy (onchocerciasis, lymphatic filariasis, schistosomiasis)
10. **Treat contacts**: Pinworm, scabies, lice, trichomoniasis

---

## Key Takeaways

1. **Malaria**: ACTs first-line for P. falciparum; chloroquine for sensitive species; primaquine for radical cure
2. **Resistance**: Major issue in malaria (chloroquine, artemisinin)
3. **Metronidazole**: Broad antiprotozoal and anaerobic coverage
4. **Benzimidazoles**: Broad-spectrum antihelminthics
5. **Ivermectin**: Strongyloides, filarial worms, ectoparasites
6. **Praziquantel**: Drug of choice for schistosomiasis and most tapeworms
7. **G6PD deficiency**: Screen before primaquine, dapsone (hemolysis risk)
8. **Pregnancy**: Many antiparasitics contraindicated (benzimidazoles, primaquine)
9. **Mass treatment**: Essential for control of neglected tropical diseases
10. **Global health**: Parasitic diseases major burden in resource-limited settings

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. WHO Guidelines for Malaria, 2023
4. CDC Yellow Book: Travelers' Health, 2024
5. CDC Guidelines for Treatment of Parasitic Infections, 2023
